UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 26, 2004
VASO ACTIVE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware | | 001-31925 | | 02-0670926 |
(State or other jurisdiction
of incorporation No.) | | (Commission File No.) | | (IRS Employer
Identification No.) |
99 Rosewood Drive, Suite 260, Danvers, Massachusetts 01923
(Address of principal executive offices including zip code)
(978) 750-0090
(Registrant’s telephone number, including area code)
TABLE OF CONTENTS
2
ITEM 5. OTHER EVENTS
On February 26, 2004, Vaso Active Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that on February 19, 2004, the number of directors on the Board of Directors of the Company (the “Board”) had been increased to eight and that Kevin J. Seifert, the Chief Operating Officer of the Company, had been appointed to the Board.
ITEM 7. EXHIBITS
(c) Exhibits.
Exhibit 99.1 - Press Release, dated February 26, 2004.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| VASO ACTIVE
PHARMACEUTICALS, INC. |
| | |
| | |
| By: | /s/ John J. Masiz | |
| | Name: John J. Masiz |
| | Title: President, CEO |
| | |
Date: February 26, 2004 | | |
3
